RedHill Biopharma (RDHL) Change in Receivables: 2012-2022
Historic Change in Receivables for RedHill Biopharma (RDHL) over the last 11 years, with Dec 2022 value amounting to $1.5 million.
- RedHill Biopharma's Change in Receivables rose 190.55% to $1.5 million in Q4 2022 from the same period last year, while for Dec 2022 it was -$2.8 million, marking a year-over-year increase of 5.83%. This contributed to the annual value of $52,000 for FY2024, which is 99.84% down from last year.
- According to the latest figures from Q4 2022, RedHill Biopharma's Change in Receivables is $1.5 million, which was up 165.94% from -$2.3 million recorded in Q3 2022.
- RedHill Biopharma's 5-year Change in Receivables high stood at $6.1 million for Q3 2020, and its period low was -$16.9 million during Q2 2020.
- Its 3-year average for Change in Receivables is -$2.8 million, with a median of -$1.1 million in 2020.
- Over the last 5 years, RedHill Biopharma's Change in Receivables had its largest YoY gain of 5,487.27% in 2020, and its largest YoY loss of 3,787.75% in 2020.
- RedHill Biopharma's Change in Receivables (Quarterly) stood at $1.8 million in 2018, then crashed by 126.19% to -$473,000 in 2019, then slumped by 3,331.50% to -$16.2 million in 2020, then surged by 89.90% to -$1.6 million in 2021, then skyrocketed by 190.55% to $1.5 million in 2022.
- Its Change in Receivables was $1.5 million in Q4 2022, compared to -$2.3 million in Q3 2022 and -$7.8 million in Q2 2022.